Sentence examples for breakpoints were used for from inspiring English sources

NCCLS breakpoints were used for interpretation of MIC's [ 29].

However, because no breakpoints have been established for levofloxacin and gatifloxacin, moxifloxacin breakpoints were used for interpretation of these results.

FDA breakpoints were used for doripenem since CLSI breakpoints for doripenem were not available when the study was initiated.

Susceptibility to daptomycin was defined as MIC <1 mg/L (5 ); CLSI guideline MIC breakpoints were used for all other drugs tested (4 ).

Susceptibility to daptomycin was defined as a MIC value of ≤ 1 mg/L; CLSI guideline MIC breakpoints were used for all the other antibiotics tested [ 27].

The following breakpoints were used for cefazolin (S, ≥ 28 mm; I, 26 27 mm and R, ≤ 25 mm) [ 7] and for imipenem (S, ≥ 30 mm).

Previously, a single set of interpretative breakpoints was used for both meningeal and nonmeningeal isolates.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used [ 21]: Breakpoints for the definition of decreased cefixime and ceftriaxone susceptibility were MICs >0.125 mg/L, and ciprofloxacin resistance was defined by MICs >0.064 mg/L.

Antimicrobial susceptibility was determined using CLSI-approved breakpoints [ 13] with the exception of tigecycline, for which US Food and Drug Administration (FDA -approved breakpoints were used as CLSI breakpoints are not available FDA -approvedne [ 15].

Antimicrobial susceptibility patterns were determined using broth microdilution at the CDC Streptococcus laboratory (Atlanta, US), and minimum inhibitory concentrations for nonmeningitis breakpoints were used according to standard interpretative criteria [ 19].

Clinical and Laboratory Standards Institute (CLSI, formerly National Committee for Clinical Laboratory Standards) breakpoints were used to determine levels of resistance for all antimicrobial agents except mupirocin, for which no CLSI breakpoints exist (28 ).